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E-mail address: rsackstein@rics.bwh.harvard.edu (Despite great strides in our knowledge of the genetic and epigenetic changes underlying malig-
nancy, we have limited information on the molecular basis of metastasis. Over 90% of cancer deaths
are caused by spread of tumor cells from a primary site to distant organs and tissues, highlighting
the pressing need to deﬁne the molecular effectors of cancer metastasis. Mounting evidence sug-
gests that circulating tumor cells (CTCs) home to speciﬁc tissues by hijacking the normal leukocyte
trafﬁcking mechanisms. Cancer cells characteristically express CD44, and there is increasing evi-
dence that hematopoietic cell E-/L-selectin ligand (HCELL), a sialofucosylated glycoform of CD44,
serves as the major selectin ligand on cancer cells, allowing interaction of tumor cells with endothe-
lium, leukocytes, and platelets. Here, we review the structural biology of CD44 and of HCELL, and
present current data on the function of these molecules in mediating organ-speciﬁc homing/metas-
tasis of CTCs.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cancer deaths are generally caused by dissemination of cancer
cells from a primary site to distant organs and tissues [1]. Despite
intensive research into the pathobiology of cancer, our understand-
ing of the metastatic process remains largely incomplete. Hema-
togenous metastasis is a complex, multi-step process in which
cancer cells detach from the primary tumor, enter the blood circu-
lation, avoid destruction by hemodynamic forces and the immune
system, migrate to and extravasate into distant tissues, and, ﬁnally,
seed and establish a secondary tumor [2]. Each of these sequential
steps can be rate-limiting and failure at any step may prevent for-
mation of a secondary lesion. Indeed, although millions of tumor
cells may escape into the circulation every day, only a very small
fraction successfully executes all the steps of the metastatic cas-
cade and colonizes a distant organ [3–5]. The critical initiatingchemical Societies. Published by E
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R. Sackstein).event in target tissue inﬁltration involves the attachment of circu-
lating tumor cells (CTCs) to vascular endothelium with sufﬁcient
strength to overcome the prevailing forces of blood ﬂow. Since this
‘‘braking’’ process is, literally, the ﬁrst step in tissue colonization, it
is a focus of intense investigations aimed at yielding novel thera-
peutic strategies to contain and/or limit cancer dissemination.
The molecular effectors that mediate cancer metastasis are best
known for their role(s) in directing normal leukocyte trafﬁcking,
such as to lymphoid organs and to sites of inﬂammation and tissue
injury. The braking adhesive interactions of ﬂowing cells onto the
vascular endothelium consist of shear-resistant tethering and roll-
ing of circulating cells onto the endothelial surface. This primary
step is mediated principally by the selectin class of adhesion mol-
ecules. The selectins comprise a family of three lectins that bind
sialofucosylated glycans on their respective ligands. One of these
selectin ligands, known as hematopoietic cell E-/L-selectin ligand
(HCELL), is a specialized sialofucosylated glycoform of CD44 that
is characteristically expressed on human hematopoietic stem cells.
HCELL is the most potent E-selectin and L-selectin ligand expressed
on human cells [6–8]. Its ‘‘scaffold’’ protein, CD44, otherwise best
known for serving as the principal receptor for hyaluronic acid
(HA), is a multistructural and multifunctional molecule that is in-
volved in a plethora of physiological and pathological processes,
including cancer metastasis [9,10]. CD44 is prominently expressed
on malignant cells; in fact, CD44 has been identiﬁed as a cancer
stem cell (CSC) marker, and, notably, various human malignancies
express the HCELL glycoform. In this review, we focus on thelsevier B.V. All rights reserved.
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into their role(s) in hematogenous metastasis.
2. The multi-step paradigm of cellular trafﬁcking: the critical
‘‘roll’’ of step 1
Recruitment of cells from the bloodstream into tissues is a
highly regulated process that is central to multiple physiologic
and pathologic processes, including inﬂammation, tissue repair,
and metastasis. According to the multi-step paradigm of cellular
trafﬁcking (Fig. 1), extravasation is initiated by tethering and roll-
ing interactions of blood-borne cells on the endothelial surface
(step 1). Interaction of the rolling cells with locally produced che-
mokines subsequently results in integrin activation (step 2), which
leads to ﬁrm adhesion (step 3) and ﬁnally, transmigration across
the endothelium into the tissue (step 4) (Fig. 1).
The critical ﬁrst step for all vascular emigration is the decelera-
tion of circulating cells on target endothelium to velocities well be-
low the local blood ﬂow rate. Cells ﬁrst tether to the luminal side of
the blood vessel wall, then start rolling and ﬁnally transition into a
process called ‘‘slow rolling’’. The most potent mediators of this
physiologic deceleration process are the selectins, a family of three
‘‘C-type’’ lectins that bind to sialofucosylated proteins or lipids in a
calcium-dependent manner. Though structurally related, the tissue
distribution of selectins is distinct and largely non-overlapping. E-
selectin (CD62E) is expressed exclusively on endothelial cells. In
skin [11] and bone marrow microvasculature [12–14] its expres-
sion is constitutive. In most other tissues, however, E-selectin
expression requires de novo synthesis following exposure to
inﬂammatory stimuli, like TNF-a, IL-1b and LPS [15]. Following
cytokine stimulation of cultured human umbilical vein endothelial
cells (HUVECs), E-selectin surface expression typically peaks at 3–
4 h and returns to baseline after 16–24 h [16].
In contrast to E-selectin, expression of P-selectin (CD62P),
which can be found on both endothelial cells and platelets, does
not require de novo synthesis. Though cytokines induce transcrip-
tion of P-selectin mRNA and subsequent protein production, P-
selectin is stored in Weibel-Palade bodies of endothelial cells andFig. 1. The multi-step paradigm of cellular trafﬁcking. The critical ﬁrst step for all vascu
process mediated by selectins and their ligands (step 1). The commonminimal binding de
necessary for the cells to ‘taste’ the local milieu, i.e., to interact with locally produced ch
(step 2), which results in ﬁrm adhesion (step 3) and ﬁnally, transendothelial migrationin a-granules of platelets. As a result, P-selectin can be mobilized
to the surface within seconds (platelets) to minutes (endothelial
cells) in response to a variety of inﬂammatory mediators [15,17].
After 30–60 min, however, P-selectin is internalized again by endo-
cytosis and a subset is recycled back into theWeibel-Palade bodies.
This recycling is not observed for E-selectin, which is endocytosed
as well, but is sorted from endosomes to lysosomes, where it is
subsequently degraded [18]. In rodents, in addition to rapid cell
surface mobilization of preformed P-selectin, de novo P-selectin
synthesis can be induced by TNF-a and IL-1b with similar kinetics
as seen for E-selectin [19]. Notably, on human endothelial cells,
neither TNF-a nor IL-1b nor LPS can upregulate P-selectin expres-
sion [20]. However, the cytokines IL-4 and oncostatin M have been
observed to induce prolonged P-selectin expression on HUVEC, an
effect lasting up to 72 h [20].
L-selectin (CD62L) is well-recognized for its key function in
directing lymphocyte trafﬁcking to lymphnodes and is also involved
in regulatingmigration of leukocytes to sites of inﬂammation. Apart
from mediating endothelial adhesive interactions, L-selectin plays
an important role in cell migration via secondary tethering [21],
i.e., initiation of tethering and rolling of circulating leukocytes on
each other through interaction with previously arrested leukocytes.
Thisprocess allows leukocytes thatdonot express ligands for E- or P-
selectin to home to sites of inﬂammation. L-selectin is expressed
constitutively byhematopoietic stemcells,myeloid cells, naïve lym-
phocytes, central memory T cells and regulatory T cells, but effector
memory T cells do not typically express L-selectin [22]. L-selectin
expression is principally regulated by membrane shedding: follow-
ing cell activation, membrane L-selectin levels are rapidly (within
minutes) downregulated by proteolytic cleavage [23].
L-selectin predominantly mediates fast rolling (>50 lm/s),
engagement of P-selectin promotes rolling at 20–50 lm/s, and E-
selectin mediates slow rolling at velocities typically below
10 lm/s [24–26]. Notably, though the selectins are the most potent
mediators of step 1, several other molecules are able to mediate
tethering and rolling adhesive interactions. Neutrophils seques-
tered in liver sinusoids typically do not roll, but rather tether and
then immediately transition to ﬁrm adhesion. This process haslar emigration is the deceleration of blood-borne cells on the endothelial surface, a
terminant for all three selectins is the tetrasaccharide sialyl-Lewis x (sLex). Rolling is
emotactic stimuli. Successful chemokine signaling results in activation of integrins
(step 4).
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sively on leukocyte surface CD44 binding to endothelial HA depos-
its [28]. Besides CD44, integrins can support rolling (either alone
[29] or in conjunction with selectins [30]) or, in some cases, can
mediate rapid ﬁrm adhesion without prior rolling [31].
Rolling directly onto the endothelium is necessary for the cells
to ‘taste’ the local milieu, i.e., to interact with chemotactic
stimuli (principally chemokines) characteristically presented by
glycosaminoglycans (GAGs) on the luminal and abluminal sides
of the blood vessel (Fig. 1) [32–34]. According to the classical
model of cellular trafﬁcking, it is the expression of compatible
combinations of chemokine receptors (on circulating cells) and
chemokines (by target endothelium) that allows tissue-speciﬁc
recruitment of selective subsets of circulating cells. Rolling cells
that do not express the cognate receptor for the chemokines pro-
duced by the underlying tissue are unable to transition to ﬁrm
adherence and subsequent transmigration into the tissue; for these
cells, rolling is transient and they will eventually detach from the
blood vessel wall and re-enter into the circulation.
Successful chemokine signaling results in a rapid (milliseconds)
activation of integrins on the surface of rolling cells [35]. Chemo-
kine-dependent inside-out signaling increases cell adhesiveness
(avidity) through: (1) integrin conformational changes, leading to
a high-afﬁnity binding state; and (2) altering local integrin density,
leading to increased valency [36]. Activated integrins subsequently
bind to their endothelial ligands resulting in leukocyte arrest on the
vascular endothelium. Integrin-dependent ﬁrm adhesion of leuko-
cytes is mostly mediated by b1- and b2-integrins binding to respec-
tive endothelial ligands, typically VLA-4 (a4b1; CD49d/CD29)
binding to VCAM-1, and LFA-1 (aLb2; CD11a/CD18) binding to
ICAM-1. Following ﬁrm adhesion, monocytes, neutrophils and T
cells undergo b2-integrin-mediated intravascular crawling, seeking
appropriate sites of transendothelial migration [32,37–39]. This
crawling process, however, is not random. It has recently been
shown that an intravascular chemokine gradient bound to endothe-
lial heparan sulfate directs intraluminal crawling neutrophils to-
ward transmigration loci [40]. The majority of emigrating cells
transmigrate into the tissue via the paracellular route, i.e., through
intercellular junctions. A small minority of leukocytes (4–15%
in vitro [41]), however, prefers the transcellular route, i.e., through
individual endothelial cells.
Though chemokine signaling imparts speciﬁcity to cellular
recruitment, it is important to note that transendothelial migration
mayoccur in absence of chemokine input.We recently reported that
human mesenchymal stem cells (MSC), glycoengineered to express
HCELL on their cell surface, efﬁciently home to and extravasate into
bonemarrow parenchyma [42]. The fact that the humanMSCs used
in these studies did not express the chemokine receptor CXCR4,
which is essential for recruitment of hematopoietic stem/progenitor
cells (HSPCs) to bone marrow, suggested the existence of a chemo-
kine-independent pathway for transendothelial migration. Indeed,
recent studies from our lab indicate that ligation of HCELL or CD44
(by E-selectin or HA, respectively) on the surface of human MSCs
triggers VLA-4 activation and subsequent binding of its ligands
VCAM-1 and ﬁbronectin. HCELL+ MSCs, but not HCELL MSCs, are
able to transmigrate on E-selectin- and VCAM-1-expressing HUVEC
monolayers, without chemokine signaling [43]. These ﬁndings
indicate that some cell types, like human MSCs, can employ
chemokine-independent effectors of cell trafﬁcking, thereby
achieving tissue-speciﬁc migration via a ‘step 2-bypass pathway’.
3. Selectin ligands
The common minimal binding determinant for all three selec-
tins is the tetrasaccharide known as sialyl-Lewis x (sLex) and itsisomer, sialyl-Lewis a (sLea). High resolution NMR spectroscopy
has revealed that E-selectin binds sLex with the highest afﬁnity;
L- and P-selectin, respectively, display a 5- and 10-fold lower afﬁn-
ity [44]. Despite the low afﬁnity of monovalent sLex–selectin inter-
action, high-avidity interactions can be generated by multivalent
ligand presentation. In addition, further substitution of sLex with
a sulfate ester on the 6-hydroxyl group of N-acetylglucosamine
(GlcNAc) (i.e., 6-sulfo-sLex) signiﬁcantly increases its afﬁnity for
L-selectin [45]. This modiﬁcation is characteristic for L-selectin
ligands expressed on endothelial cells such as high endothelial
venules of mouse lymph nodes and human tonsils, e.g., CD34,
GlyCAM-1, MadCAM-1, podocalyxin, and endomucin. Collectively,
these selectin ligands are known as peripheral lymph node addres-
sins (PNAd) [45]. The 6-sulfo-sLex glycotopes are typically pre-
sented on O-glycans, although they can be present on N-glycans
as well [46]. On the major leukocyte ligand for P-selectin, P-selec-
tin glycoprotein ligand-1 (PSGL-1), sulfation of speciﬁc tyrosine
residues in close proximity to sLex-bearing glycans renders higher
afﬁnity binding to both P- and L-selectin without requirement for
glycan sulfation [47,48].
Efﬁcient selectin binding to its ligand(s) requires the carbohy-
drate moiety to be presented on either a protein (i.e., glycoprotein)
or lipid (i.e., glycolipid) scaffold. The best characterized selectin li-
gands are glycoproteins that carry terminal sLex/a glycotopes on O-
and/or N-glycans. However, despite the presence of hundreds of
(glyco)proteins at the cell surface [49], only a handful function as
selectin ligands. The reason for this remarkable speciﬁcity in sLex
display is unknown. Indeed, CD44, a ubiquitously expressed pro-
tein, is decorated with sLex (thus, HCELL) on only a select subset
of cells, and this remarkable speciﬁcity in HCELL expression is
one of the most intriguing examples of CD44 pleiotropism.
4. CD44 pleiotropism and cancer metastasis
CD44 is a class I integral membrane glycoprotein involved in
many physiological and pathological processes. Though known
best as a receptor for HA, a linear polysaccharide composed of
repeating units of GlcNAc and glucuronic acid [50], CD44 can inter-
act with various other extracellular matrix components including
chondroitin sulfate, ﬁbrinogen, ﬁbronectin, collagen and laminin.
In addition, CD44 has been reported to bind mucosal vascular
addressin, osteopontin, serglycin/gp600, and the MHC class II
invariant chain [51]. The various adhesive capabilities of CD44
makes this molecule a hub for directing both cell–cell and cell–ma-
trix interactions. This functional diversity is a reﬂection of the
broad structural heterogeneity of CD44 which arises in part from
the differential incorporation of nine alternatively spliced exons
(10 in mice), and in part from a wide range of post-translational
modiﬁcations, such as N- and O-glycosylation, and GAG substitu-
tions (e.g., chondroitin sulfation). As a result, CD44 molecules
range in molecular weight from 80 to over 200 kDa [10]. The small-
est isoform, known as hematopoietic or standard CD44 (CD44s), is
expressed on the surface of most mammalian cell types and
contains none of the alternatively spliced exons. Although it has
a theoretical molecular weight of 37 kDa, it typically runs on
SDS–PAGE gels at 80–95 kDa due to extensive glycosylation.
CD44 is structurally composed of an extracellular globular
lectin-like domain, a membrane-proximal stem region, a trans-
membrane domain, and a cytoplasmic tail. Incorporation of splice
peptide sequences, encoded by so-called ‘variant’ exons, occurs in
the stem region. Besides encoding amino acids, some variant exons
contain additional motifs for glycosylation (particularly O-glycan
substitutions) and for GAG addition, each of which substantially
increases protein molecular weight. For example, the entire CD44
variable region contains only four potential N-glycosylation sites,
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encoded by variant exon v9 are serine and threonine residues) [51].
As a result, CD44 variant (CD44v) isoforms can become quite large;
one of the largest CD44 variants (CD44v3–v10, also referred to as
‘‘epican’’) is expressed on keratinocytes and has a molecular weight
of 230 kDa [52].
Numerous published reports have shown that CD44 is essential
to many tumor cell activities. In addition, CD44 has been linked to
the metastatic potential of a variety of cancers (comprehensively
reviewed by Naor et al. [53]). Upregulation of CD44s and/or
CD44v isoforms in malignant tissues compared to their benign
counterparts has been shown for a variety of cancers. At the same
time, however, contradictory observations of unchanged and even
reduced CD44 expression in the same neoplastic disease have been
reported as well [54–56]. Similar observations have been made
regarding the association between expression of speciﬁc CD44 iso-
forms and tumor progression from benign to highly malignant
stages. Some studies report a gradual increase in the expression
of CD44v isoforms from early to late adenoma, and from non-
metastatic to metastatic carcinoma, for example, in colon cancer
[57–59] and in melanoma [60,61]. However, other researchers re-
ported reduced levels of CD44 in the metastatic phase of colorectal
cancer [62,63] or even a complete lack of correlation between dis-
ease stage and CD44 isoform expression [64,65]. These seemingly
inconsistent ﬁndings are reﬂected in the value of CD44 expression
as a prognostic marker for cancer. Not only has an unfavorable out-
come been associated with either upregulation or downregulation
of CD44 on tumor cells, different groups studying the same neo-
plastic disease have come to opposite conclusions, i.e., poor versus
favorable prognosis for a speciﬁc cancer [53]. The reasons for these
contradictory ﬁndings are not entirely clear, but it is believed that
in many cases they are technical in nature and/or due to differ-
ences in experimental design [53]. Therefore, standardization of
techniques and approaches to analyze CD44 on human cancers
across laboratories will help obtain more consistent data from
patient specimens.
4.1. Regulation of CD44 function by glycosylation
The activation state of CD44 is dictated by the cell in which it is
expressed. Three activation states have been recognized: inactive,
inducible and constitutively active [66]. Though CD44 is present
on a wide variety of cell types, it is most often in an inactive form.
However, cells can switch CD44 to an active binding state upon
exposure to various stimuli. Resting B cells, for example, hardly
bind HA despite high levels of CD44s on their cell surface. Follow-
ing stimulation with IL-5, a subset of the lymphocytes binds HA to
a high degree in a CD44-dependent manner. This switch to an ac-
tive HA binding state requires hours to days and is associated with
a decrease in molecular weight caused by N-glycosylation changes
[67].
Whereas the overall N-glycosylation status of CD44 typically is
inversely correlated with its capacity to bind HA (i.e., inactive CD44
is generally heavily N-glycosylated, and active CD44 tends to be
poorly glycosylated [68,69]), results of studies on the effects of
N-glycosylation on CD44 activity have been conﬂicting depending
on cell type(s). In some cases (Chinese hamster ovary cells), enzy-
matic (PNGase F) and chemical (tunicamycin) de-N-glycosylation
improves HA binding [69]; in other cases (e.g., in human lym-
phoma and melanoma cells), HA binding is prevented by such
treatment [70]. In some cell lines (RAW 253 and L cells ﬁbroblasts),
treatment with deoxymannojirimycin (dMM), which inhibits fur-
ther processing of high mannose-type N-glycans, has no effect on
HA binding [68], while in other cell lines (a RAW 253 variant and
T24 bladder carcinoma cells), dMM treatment enhances binding,
suggesting an inhibitory effect of complex-type N-glycans [68,70].It has been well established that neuraminidase treatment of
cells or puriﬁed CD44-Ig fusion proteins increases their ability to
bind HA [69,71,72]. Possibly, since both sialic acid and HA are neg-
atively charged, sialylation of CD44 blocks HA binding via charge
repulsion. Notably, peripheral blood monocytes express high levels
of cell surface CD44 yet do not bind HA [73]. Upon activation with
LPS, a functionally active HA-binding form of CD44 is induced by
activation of a lysosomal sialidase [73–75]. Similarly, peripheral
blood lymphocytes do not bind HA [73]. Following activation, how-
ever, T cells transiently switch CD44 to an active HA binding state
[76]. In a mouse model for induced allergic asthma, airway
accumulation of Th2 cells is critically dependent on CD44. It has
recently been shown that activation of CD44 is dependent on the
induction of Neu1 sialidase [77]. Although the latter is a lysosomal
enzyme, it has been detected on the cell surface of both monocytes
[78] and activated T cells [79]. In fact, mounting evidence
suggests that desialylation is an important mechanism in many
(patho)physiological processes, allowing cells to rapidly modulate
the activation state of cell surface receptors and ligands [80–83].
Few studies have looked into the effect of speciﬁc glycosyltrans-
ferases on HA binding. B16 melanoma cells stably transfected to
express b-1,4-N-acetylglucosaminyltransferase III (GnT-III) show
an increased ability to bind HA. It has been suggested that addition
of bisecting GlcNAc (via GnT-III) inhibits poly-LacNAc elongation
and b-1,6-branching, resulting in fewer antennae that tend to be
truncated [84,85]. CD44 from these cells is less heavily glycosyl-
ated (decreased molecular weight on SDS–PAGE), and is both hyp-
ogalactosylated and hyposialylated, again pointing towards
inhibitory effects of sialylated complex-type N-glycans [86].
Human CD44 has six potential N-glycosylation sites (Asn25,
Asn57, Asn100, Asn110, Asn120 and Asn255), the ﬁrst ﬁve of which
are located within the HA binding domain. Inactivation of individ-
ual N-glycosylation sites by site-directed mutagenesis has shown
that N-glycans at Asn25 and Asn120 are involved in modulating
HA binding since their inactivation converted an inducible HA
binding cell line to constitutively active [71]. None of the muta-
tions, however, had any effect on the HA binding ability of an ac-
tive cell line, indicating that more subtle, cell-speciﬁc changes in
N-glycosylation are sufﬁcient to modulate HA binding by CD44.
Nevertheless, elucidation of the 3D structure of the HA binding do-
main of CD44 has provided a mechanistic explanation of how gly-
cans attached to Asn25 and Asn120 might regulate CD44 function.
N-glycans at position 25 could directly impact HA binding by mod-
ulating CD44 afﬁnity for its ligand; conversely, oligosaccharides at-
tached to Asn120 might impact CD44 homo-oligomerization, as
such regulating HA binding avidity [87,88].
O-Glycosylation can enhance [72,89], decrease [90], or not
inﬂuence binding to HA at all [68,91]. Bennett et al. showed that
the reduced HA binding ability of CD44v8–v10 is due to the addi-
tion of O-glycans to the variable exons [90]. Several variably
spliced CD44 domains are rich in serine and threonine residues
(Ser/Thr content varies from 18% for exon v5 to 43% for exon v9),
suggesting that O-glycosylation of these exons might play a role
in modulating the lectin activity of CD44v isoforms.
TNF-a and IFN-c stimulation of peripheral blood monocytes
(but not T cells) increases the sulfation of CD44 and induces
HA binding. A positive correlation between CD44s sulfation and
HA binding has been shown, indicating that sulfation is yet an-
other mechanism by which cells can regulate the activation state
of CD44 [92]. Subsequent studies with cell lines demonstrated
that TNF-a-induced sulfation occurs on both N- and O-linked gly-
cans; at the same time, chondroitin sulfate addition was de-
creased [93]. More recently, it has been shown that chondroitin
sulfate addition to serine 180 of CD44s negatively regulates HA
binding by CD44-Ig fusion proteins [94] and mouse macrophages
[95].
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groups using different cell lines and various experimental ap-
proaches make it hard to formulate generally applicable principles
for the role(s) of glycosylation in regulating CD44 activity. In addi-
tion, multiple studies have artiﬁcially altered CD44 post-transla-
tional modiﬁcations in an attempt to elucidate how they
modulate HA binding. It remains unclear how such ﬁndings pro-
vide physiological insights since reagents commonly used in such
studies (tunicamycin, dMM, benzyl-a-GalNAc) affect glycosylation
of all surface glycoproteins and, as a consequence, potentially
interfere, either directly or indirectly, with multiple physiological
processes on the cell surface, not just involving CD44. In this re-
gard, site-directed mutagenesis of potential glycosylation sites is
a more elegant approach. However, this approach comes with its
own limitations since the HA binding ability of CD44 mutants
might be affected in an indirect way due to problems with protein
folding, stability and secretion. As a result, many questions remain
unanswered, and the full impact of CD44 glycan modiﬁcations in
cancer metastasis remains to be established. For example, how
do the glycomes of cells that have inactive, inducibly active, and
constitutively active CD44 on their cell surface differ from each
other? Or, similarly, what do cell types with the same CD44 activa-
tion state have in common? What array of glycans is present on
CD44 from different cell types? What range of glycan structures
is associated with each N-glycan site? Recent technological ad-
vances in high-throughput transcript analysis [96] and glycome
proﬁling [97] may help identify the speciﬁc glycosyltransferases
which regulate CD44 glycosylation and elucidate how the resulting
oligosaccharide structures modulate HA binding.
5. HCELL
The recognition of the HCELL glycoform of CD44 in studies per-
formed in the 1990s and early 2000s added measurably to the al-
ready complex tapestry of glycosylation modiﬁcations of CD44
(reviewed in [98]). HCELL, a sialofucosylated glycoform of CD44
characteristically displayed on human HSPCs, functions as the
most potent E- and L-selectin ligand found on human cells. Thus,
not only is CD44 a lectin, it can also serve as a lectin ligand (i.e.,
a receptor for selectins). The latter function strikingly separates
HCELL from CD44. Despite the fact that CD44s is modiﬁed with
both O- and N-linked glycans, the sLex glycotopes that mediate
the E- and L-selectin ligand activity of HCELL on HSPCs are dis-
played exclusively on N-glycans on CD44s. It is presently unclear,
though, to what extent each of the six potential N-glycosylation
sites on CD44s contribute to the selectin ligand activity of HCELL,
and current studies in our lab are directed to this question. Nota-
bly, in contrast to most other L-selectin ligands, binding of HCELL
by this selectin is sulfation-independent and, consistent with N-
glycan presentation of sLex, is resistant to O-sialoglycoprotease
digestion [99,100].
Although CD44 is present on many cell types, expression of
HCELL is natively restricted to human HSPCs and is not found on
mouse HSPCs [7,101]. Conspicuously, G-CSF-mobilized peripheral
blood leukocytes express high levels of HCELL [102]. HCELL has
also been shown to be present at high levels on human malignant
hematopoietic cells, including de novo acute myeloid leukemia
(AML) cells and the AML-derived primitive human hematopoietic
progenitor cell line KG1a [6,7,99]. More recent studies have shown
that colon cancer cells [103–105] and breast cancer cells [106] ex-
press an alternative form of HCELL. It is characterized by presenta-
tion of sialofucosylated glycotopes on O-glycans on CD44v
isoforms. In line with the CD44 nomenclature currently in general
use, HCELL activity on CD44s versus CD44v isoforms is referred to
as HCELLs and HCELLv, respectively. Both HCELL isoforms differfrom each other on two fundamental levels: protein backbone
(CD44s versus CD44v) and glycosylation (the type of glycans that
display the selectin binding determinants, i.e., N- versus O-linked
oligosaccharides). As a result, both HCELL isoforms have a signiﬁ-
cantly different molecular weight: HCELLs migrates as a 90–
100 kDa band on SDS–PAGE gels, while HCELLv from colon cancer
cells typically has a molecular weight of about 150 kDa. Interest-
ingly, colon cancer cells express HCELLv and CD44s, but not HCELLs
[105]. Despite these differences, shear-based in vitro assays have
shown that HCELLs and HCELLv are otherwise equally potent E-
and L-selectin ligands [98,104].
6. CD44, HCELL, and the molecular basis of metastatic tissue
tropism(s)
Some types of cancer show an organ-speciﬁc pattern of hema-
togenous metastasis. For breast cancer, the four leading metastatic
sites are lung, liver, bone and brain [107]. Colorectal cancer com-
monly spreads to the liver, the lungs and, to a lesser extent, the
bone [108]. In contrast, prostate tumor cells characteristically
metastasize to bone, although the lungs and the liver are major tar-
get organs as well [109]. Melanoma, on the other hand, typically
metastasizes to brain, lungs, and skin [110].
An issue of controversy in this regard has been whether the tis-
sue tropism of certain cancers is caused by mechanical trapping
within capillaries or by speciﬁc interactions with microvascular
endothelial cells. The mechanical trapping theory, formulated by
James Ewing in the 1920s, hypothesizes that circulatory patterns
dictate the tissue distribution of metastases and that metastasis
to distant organs essentially is a passive process [111]. Ewing for-
mulated his theory to challenge the ‘seed and soil’ hypothesis pub-
lished in 1889 by Stephen Paget, proposing that cancer cells (the
seed) require a compatible microenvironment (the soil) provided
by the target tissue in order to successfully form a secondary tu-
mor [112]. In this view, metastasis is an active lodgment process
that requires the expression of a compatible set of proteins by CTCs
and the microvascular environment of the target distant organ. Our
increasing understanding of tissue-speciﬁc patterns of metastasis
based on endothelial expression of relevant effectors of cell migra-
tion has shifted attention away from the stochastic mechanical
entrapment theory, pointing instead to an active homing model
similar to that of leukocyte recruitment. Mounting in vitro and
in vivo evidence suggests that cancer cells home to speciﬁc tissues
by hijacking the normal leukocyte trafﬁcking mechanisms by
expressing selectin ligands, chemokine receptors and/or integrins
on their cell surface.
Malignant transformation is associated with changes in the cel-
lular glycosylation machinery, resulting in cell surface expression
of tumor-associated carbohydrate antigens like sLex and sLea. The
presence and level of sLex/a expression is often associated with can-
cer progression, metastatic spread and poor prognosis [113]. In
fact, sLex and sLea were originally identiﬁed as tumor antigens
[114]. As discussed earlier, the normal physiological role of these
carbohydrate antigens is to mediate the earliest steps of leukocyte
trafﬁcking by interaction with their receptors, the selectins. Con-
vincing data now suggests that, analogous to leukocyte recruit-
ment to sites of inﬂammation, the observed tissue tropism of
certain cancers is in part the result of CTC–endothelial cell interac-
tions mediated by selectins and cognate selectin ligands expressed
on cancer cells [5,115]. Mechanistically, tumor metastasis is facili-
tated by selectin-mediated interactions between cancer cells and
endothelial cells, leukocytes and platelets (Fig. 2). Our emerging
data highlight the critical contributions of the step 1 effectors
CD44 and HCELL in directing homing of CTCs to permissive meta-
static sites.
Fig. 2. The molecular basis of metastatic tissue tropism(s): CD44 and HCELL. Tumor cells home to speciﬁc tissues by hijacking the normal leukocyte trafﬁcking mechanisms
by expressing selectin ligands on their cell surface. The principal selectin ligand on cancer cells, HCELL, allows CTCs to interact with E- and P-selectin on activated
endothelium, L-selectin on leukocytes and P-selectin on platelets. Organs that do not constitutively express E-selectin, like the liver and the lungs, can be induced to do so by
intravascular LPS (derived from the gut) and by pro-inﬂammatory cytokines (produced by the primary tumor or by cells from the immune system). In addition to E-selectin-
mediated interactions, the CD44–HA axis is important for tumor metastasis to organs rich in HA, like the liver, lungs and bone marrow. Bone marrow-derived HSPCs, known
to express both HCELL and L-selectin, home to pre-metastatic sites before the arrival of tumor cells and thus may play an important role in the establishment of the pre-
metastatic niche.
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To date, only a handful cancer-associated selectin ligands have
been identiﬁed [103,106,116–120]. Interestingly, although PSGL-
1 is one of the major selectin ligands found on leukocytes, it is of-
ten conspicuously absent on non-leukemic cancer cells [121–123].
In contrast, HCELL, which is typically only found on HSPCs, is now
recognized as being one of the dominant selectin ligands on cancer
cells. Leukemic blasts, particulary in acute myelogenous leukemia,
express copious amounts of HCELLs. In contrast, malignant cells
of solid cancers predominantly express HCELLv isoforms
[103,105,106]. LS174T colon cancer cells express HCELLv isoforms
composed of variant regions v3, v5, v7, v8 and v10; variant regions
v4, v6 and v10 are present in a smaller percentage of the HCELLv
isoforms [103]. On SDS–PAGE, these HCELLv isoforms migrate as
a 150 kDa band [103]. In contrast, metastatic MDA-MB-231
breast cancer cells express high levels of a 170 kDa HCELLv4
isoform [106]. Upon down-regulation of HCELLv4 expression,
MDB-MB-231 breast cancer cell adhesion and migration across
TNF-a-activated HUVEC monolayers was signiﬁcantly reduced,
indicating that HCELLv serves as a major E-selectin ligand in medi-
ating breast cancer metastasis [106]. In both colon cancer and
breast cancer cells, siRNA-mediated knock-down of CD44 signiﬁ-
cantly reduced binding to E-selectin [104,106].
On LS174T cells, the relevant sialofucosylated glycotopes of
HCELLv are exclusively expressed on O-glycans. No information
in this regard is available for breast cancer cells. However, based
on the fact that CD44v isoforms are known to have a high Ser/Thr content, we suspect that O-glycans play an important, if not
predominant, role in this type of cancer as well.
Accumulating evidence suggests that CSCs, which are thought
to be essential for metastasis formation [124], are highly resistant
to chemo- and radiotherapy, indicating that conventional antican-
cer strategies might fail to eradicate the cell subset that is crucial
for tumorigenesis [125]. Therefore, CSC ablation represents a major
therapeutic promise for clinical cancer therapy. This could poten-
tially be achieved by targeting molecular markers speciﬁcally ex-
pressed by CSCs or expressed by both CSCs and non-CSC tumor
cell populations [126]. In this regard, CD44 has been identiﬁed as
a CSC marker for several human cancers, including colon cancer
[127], breast cancer [128], and leukemia [129], all of which express
HCELL. Since it is expressed on most normal cell types, though,
therapeutic targeting of CD44 may result in disruption of physio-
logic processes. The HCELLv glycoforms, on the other hand, are
exclusively found on cancer cells and, therefore, represent a very
promising therapeutic target. It remains to be formally demon-
strated, however, whether CSCs express HCELLv.
6.2. E-selectin-dependent organotropism and metastasis
As noted above, E-selectin is constitutively expressed on bone
marrow microvasculature. This explains, at least in part, the bone
tropism of certain selectin ligand-expressing neoplasms, for exam-
ple, breast cancer. However, with the exception of bone marrow,
most organs that frequently host metastases (e.g., liver and lungs)
express E-selectin only in an inducible way, typically as a result of
inﬂammation. Nevertheless, convincing evidence supports an
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Studies in the 1990s showed that transgenic mice overexpressing
E-selectin in the liver developed massive inﬁltrating liver tumors
upon injection with sLea-positive B16 melanoma cells [130]. In
contrast, normal mice injected with sLea-positive and negative
B16 cells and transgenic mice injected with sLea-negative B16 cells
developed lung tumors exclusively [130]. Inhibition of hepatic E-
selectin expression has been shown to block metastasis to the liver
[131]. Induction of E-selectin expression by treatment of mice with
the pro-inﬂammatory cytokine IL-1 prior to injection with several
sLex/a-positive colon carcinoma cell lines resulted in higher num-
bers of lung metastases, whereas incubation of the cancer cells
with a soluble recombinant E-selectin prior to injection blocked
metastasis [132]. Finally, injection of nude mice with an anti-sLea
antibody prior to intravenous administration of colon cancer cells
blocked metastasis to the lungs [133].
Endothelial beds in the liver and lungs are induced to express E-
selectin by inﬂammatory cytokines, and it has recently become
clear that inﬂammation is an important component of tumor pro-
gression and metastasis (see also Section 6.4) [134]. Pro-inﬂamma-
tory cytokines, like TNF-a and IL-1b, play an essential role in tumor
progression and metastasis by upregulating the expression of E-
selectin and other adhesion molecules, like VCAM-1, on endothe-
lial cells. This is illustrated by the fact that TNF-a and IL-1b
knock-out mice are resistant to liver metastasis [135–138]. Simi-
larly, anti-TNF-a therapy strongly reduces both the number and
size of liver metastases of pancreatic ductal adenocarcinoma
[139]. Both TNF-a and IL-1b can be released by the primary tumor
or by cells from the immune system. Prior to the arrival of CTCs,
soluble factors secreted by the primary tumor prepare distant tis-
sues for the arrival, engraftment and survival of metastatic tumor
cells, a concept referred to as the pre-metastatic niche [140,141].
In fact, constitutive expression of pro-inﬂammatory factors (like
TNF-a and IL-1b) from tumor microenvironment is a characteristic
feature of several neoplastic diseases and has been demonstrated
to promote metastasis [142,143]. For example, VEGF-A, TGF-b
and TNF-a released by primary B16 melanoma tumors before
metastasis to the lungs, have been shown to induce the expression
of pro-inﬂammatory chemokines speciﬁcally in the lungs, which
then leads to the recruitment of monocytes [144].
In addition to endogenous pro-inﬂammatory stimuli, exposure
to LPS (lipopolysaccharide), a membrane component of gram neg-
ative bacteria, results in endothelial E-selectin surface expression.
After every meal, small amounts of gut-derived LPS cross the intes-
tinal lumen into the systemic circulation [145]. To minimize poten-
tial deleterious effects, intravascular LPS is rapidly cleared by
circulating chylomicrons (i.e., large lipoprotein particles). Although
chylomicron-bound LPS is rapidly inactivated by the liver [146],
transient intravascular LPS results in the expression of pro-inﬂam-
matory cytokines (like TNF-a and IL-1b [147]), and itself activates
endothelial cells, leukocytes and platelets (in humans) [148], and
induces E-selectin and ICAM-1 expression in the liver and lungs
[149,150]. In fact, it has been shown that chylomicrons alone in-
duce the expression of E-selectin and VCAM-1on HUVEC to a sim-
ilar extent as LPS [151]. This association between intestinal uptake
of LPS and vascular E-selectin expression may explain why E-selec-
tin-dependent metastases are so frequently found in the liver and
the lungs, tissues that do not constitutively express E-selectin.
6.3. HA-dependent organotropism and metastasis
In addition to E-selectin-mediated interactions, the CD44–HA
axis is essential to tumor metastasis to the liver, lungs and bone
marrow. HA is a major component of the extracellular matrix
and is subject to dynamic regulation during inﬂammation [152].
Endothelial cells rapidly upregulate HA synthesis upon stimulationwith TNF-a and IL-1b [153–155]. The liver and bone marrow, two
major target organs for metastasis, are extremely rich in HA
[28,156]. Neutrophils and HSPCs have been shown to depend on
CD44–HA interactions for homing to liver and bone marrow
[28,156]. In addition, convincing experimental evidence indicates
that cancer metastasis can be inhibited in animals by targeting
CD44. Transfection of the non-metastasizing rat pancreatic carci-
noma cell line BSp73ASML with a CD44v4–v7 expression vector
conferred metastatic potential to these cells upon injection in rats
[157]. Conversely, anti-sense mediated CD44v6 downregulation
decreased liver metastasis of HT29 colon cancer cells in nude mice
following intrasplenic injection [158]. Multiple groups have dem-
onstrated the ability of anti-CD44 antibodies to prevent or reduce
metastasis [159,160]. Soluble versions of CD44 have been shown to
efﬁciently inhibit hematogenous dissemination of breast cancer
[161], lymphoma [162] and melanoma cells [163]. Finally, hyal-
uronidase injection of BALB/c mice inoculated with lymphoma
cells transfected to express CD44v4–v10 prevented lymph node
metastasis [164]. Taken together, these data show that, in addition
to E-selectin-mediated interactions, the CD44–HA axis is contribu-
tory to tumor metastasis, particularly to liver, marrow and lung.
6.4. CTC adhesion to platelets and leukocytes
It is now well-established that inﬂammation plays a key role in
many stages of tumor development, including metastasis [165].
Leukocytes and platelets promote growth of both primary tumors
and metastatic lesions [5]. The involvement of L-selectin in this
process has been demonstrated with function-blocking antibodies
and L-selectin knock-out mice. L-selectin deﬁciency was shown to
attenuate cancer metastasis, even in the absence of T- and B-lym-
phocytes, hinting at the involvement of granulocytes and/or mono-
cytes in the metastatic process [166,167]. It is hypothesized that
leukocytes help tumor cells transmigrate by inducing the transient
upregulation of endothelial selectin ligands, thereby facilitating
delivery to the (pre-)metastatic niche (Fig. 2) [167,168]. Recently,
it has been shown that bone marrow-derived HSPCs home to
pre-metastatic sites before the arrival of tumor cells and thus
may play an important role in the establishment of the pre-meta-
static niche (Fig. 2) [169]. Interestingly, in addition to HCELLs,
HSPCs express L-selectin [6,7,170].
There is abundant evidence implicating platelets in the pathobi-
ology of metastasis. Activated platelets are commonly observed in
the circulation of cancer patients [171]. Platelet activation results
in the release of a myriad of bioactive factors such as IL-8, IL-1b,
CCL5, CD40L and histamine from the a-granules and dense gran-
ules [172], which are able to stimulate endothelial cells to upregu-
late cell surface expression of adhesion molecules and release
chemokines to promote leukocyte recruitment and inﬁltration
[172]. Moreover, there is substantial evidence that CTC–platelet
interactions result in the formation of tumor microemboli that
contribute to metastasis. Cancer cells express P-selectin ligands,
including HCELLv species that bind to P-selectin [105]. In fact,
HCELLv-mediated LS174T–platelet interactions have recently been
shown under shear [173]. If true on primary colon cancer cells, this
ﬁnding has major implications for the potential role of HCELL in
cancer metastasis, since it not only allows CTCs to interact with
endothelial cells but also with L-selectin-expressing leukocytes
and with P-selectin-expressing platelets (Fig. 2). Metastasis is
attenuated by inhibition of P-selectin-mediated platelet–CTC inter-
actions, either by using P-selectin knock-out mice, treatment with
heparin, or selectively removing tumor cell P-selectin ligands
[174,175]. It is believed that platelets form a protective cloak
around CTCs. This platelet coating not only facilitates initial lod-
ging of the resulting microemboli in blood vessels, but also pro-
tects the cancer cells from cytotoxic effector cells [175].
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In this review we have, by design, focused on the pathobiology
of step 1 effectors in metastasis. Yet, there is also evidence that
step 2 effectors mediate metastatic patterns, e.g., chemokine
CXCL12 interacting with CXCR4 expressed on cancer cells facili-
tates breast cancer dissemination to bone [176]. However, because
engagement of step 2 effectors is, literally, downstream of the step
1 event, strategies to block tethering/rolling interactions would
prevent chemokine-dependent processes. To this end, future stud-
ies will explore howmodulating expression and/or activity of CD44
and of HCELL will impact metastatic organotropism. Beyond this
important goal, the remarkable speciﬁcity in expression of HCELLv
on cancer cells offers the exciting possibility that this structure
could be exploited in creation of novel therapeutic reagents (e.g.,
HCELLv-speciﬁc mAb) to achieve cancer cell-selective cytotoxicity.
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